Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Semaglutide's Long-Term impact on heart and kidneys under Real-World microscope

NCT ID NCT07424430

Knowledge-focused Sponsor: LMC Diabetes & Endocrinology Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will analyze medical records of 400 adults with type 2 diabetes or obesity to see how semaglutide affects blood sugar, heart, and kidney health over three years. Researchers will compare those taking semaglutide to those on other diabetes medications. The goal is to understand how well semaglutide works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide
What this could lead to
If successful, this study could provide real-world evidence on how semaglutide improves blood sugar, heart, and kidney health over time.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It has not started yet and relies on existing medical records.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study populations will include adults with T2D prescribed semaglutide (T2D sema cohort) or other AHA (T2D other AHA cohort) including sulfonylurea, DPP4i, and/or SGLT2i, or adults with obesity, defined as BMI equal or greater 27 kg/m2, prescribed semaglutide (obesity sema cohort), who attend an LMC Diabetes \& Endocrinology clinic

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: T2D Cohort: * A clinical diagnosis of T2D ≥ 1 year * HbA1c ≥ 6.5% (pre-index date) * Initiated semaglutide or other AHA(s) before January 1st, 2023\* * Seen by an LMC endocrinologist in the last 18 months as of the query date * ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date * Informed data consent for their medical record data to be used for research purposes Obesity Cohort: * 18 years or older * BMI ≥ 27 kg/m2 * HbA1c \< 6.5% (pre-index date) * Initiated semaglutide before January 1st, 2023\* * Seen by an LMC endocrinologist in the last 18 months as of the query date * ≥ one HbA1c value up to 6 months (± 90 days) prior to index date * Informed data consent for their medical record data to be used for research purposes Exclusion Criteria: * Clinical diagnosis of type 1 diabetes/latent autoimmune diabetes in adults (LADA) * Clinical diagnosis of T2D (obesity cohort only) * Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period * Documented history or family history of medullary thyroid carcinoma * Participation in a research study with an Investigational Product * eGFR \< 15 mL/min/1.73m2 at index date * Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort) * Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes (DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes (DM) Obesity (disorder) Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.